Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for drug discovery and development ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...

GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company specializing in addiction treatment with a current market capitalization of $5 million, has been granted a new ...

New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating ...

Adial Pharmaceuticals (ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark ...

Adial Pharmaceuticals received a U.S. patent for genetic marker-based treatment methods and completed a pharmacokinetics ...

The suzetrigine, which only acts on pain neurons, is the first innovation in analgesia in the last 20 years. "It stands out ...

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...

Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of noncancerous tumors on ...

Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once-daily oral treatment for adults with ...